In connection with the implementation of the project entitled “Design and development of nanoparticle-RNA-based drugs for use in anti-cancer therapy, including the construction of a nanoparticle platform for the targeted delivery of therapeutic nucleic acids” by Biotechna SA under contract no. 2022/ABM/06/ 00005-00 for co-funding of a commercial project under the Call for proposals for the development of targeted or personalised medicine based on medicinal products derived from nucleic acids and small-molecule compounds, the Contracting Authority is conducting market research regarding the purchase and delivery costs of the DLin-MC3-DMA lipid.
To submit a bid, please review the detailed terms of the announcement included in Request for quotation No. 22/2026 and submit the completed bid form along with the product range and price form.